Two subsequent studies confirmed that RRM1 mRNA expression levels were able to identify stage IV NSCLC patients likely to have good or poor survival when treated with gemcitabine/cisplatin (Rosell et al, 2004; Ceppi et al, 2006). This evidence concerns the gene RRM1 and non-small cell lung carcinoma.